-
EP4269400
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4269400
| EP4269400 - YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.05.2024 Database last updated on 16.11.2024 | |
| Former | The application has been published Status updated on 29.09.2023 | Most recent event Tooltip | 21.08.2024 | Deletion: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states Molecure SA ul. Zwirki Wigury 101 02-089 Warszawa / PL | [2023/44] | Inventor(s) | 01 /
CZESTKOWSKI, Wojciech 95-200 Pabianice / PL | 02 /
MAZUR, Marzena 91-158 Lodz / PL | 03 /
WANAT, Przemyslaw 04-131 Warszawa / PL | 04 /
ANDRYIANAU, Gleb Irvine, 92602 / US | 05 /
NIEDZIEJKO, Piotr 00-168 Warszawa / PL | 06 /
KOWALSKI, Michal 02-661 Warszawa / PL | 07 /
GRUZA, Mariusz Marek 04-535 Warszawa / PL | 08 /
LISIECKI, Kamil 06-100 Pultusk / PL | 09 /
POMARANSKI, Piotr 05-088 Brochow / PL | 10 /
KUSMIREK, Damian 97-216 Czerniewice / PL | 11 /
PAPIERNIK, Diana 02-495 Warszawa / PL | 12 /
DRZEWICKA, Katarzyna 01-452 Warszawa / PL | 13 /
PIWOWAR, Katarzyna 02-367 Warszawa / PL | 14 /
KRYSZTOFIAK, Katarzyna 09-410 Plock / PL | 15 /
OLCZAK, Jacek 92-701 Lodz / PL | 16 /
GOLEBIOWSKI, Adam Madison, 06443 / US | 17 /
KRZEMINSKI, Lukasz 03-287 Warszawa / PL | 18 /
BARTOSZEWICZ, Agnieszka 02-384 Warszawa / PL | [2023/44] | Representative(s) | Patpol Kancelaria Patentowa Sp. z o.o. Nowoursynowska 162J 02-776 Warszawa / PL | [2023/44] | Application number, filing date | 23170807.4 | 28.04.2023 | [2023/44] | Priority number, date | PL20220441066 | 29.04.2022 Original published format: PL 44106622 | US202263336426P | 29.04.2022 Original published format: US 202263336426 P | [2023/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4269400 | Date: | 01.11.2023 | Language: | EN | [2023/44] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.09.2023 | Classification | IPC: | C07D401/10, C07D413/10, C07D413/14, C07D417/10, C07D417/14, C07D495/04, C07D498/04, C07H15/26, A61K31/5377, A61K31/7012, C07D401/08, C07D413/08, C07D417/08 | [2023/44] | CPC: |
C07D401/08 (EP);
C07H15/26 (EP,US);
C07D413/08 (EP);
C07D413/14 (EP);
C07D417/08 (EP);
C07D417/14 (EP);
C07D495/04 (EP);
C07D498/04 (EP);
G01N21/6428 (US);
G01N2021/6439 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/23] |
| Former [2023/44] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | YKL-40-INHIBITOREN UND IHRE THERAPEUTISCHEN ANWENDUNGEN | [2023/44] | English: | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | [2023/44] | French: | INHIBITEURS DE YKL-40 ET LEURS APPLICATIONS THÉRAPEUTIQUES | [2023/44] | Examination procedure | 30.04.2024 | Amendment by applicant (claims and/or description) | 30.04.2024 | Examination requested [2024/23] | 30.04.2024 | Date on which the examining division has become responsible |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2015095701 (INST DRUG DELIVERY [US]) [A] 1-35* claims 1,13 *; | [A]WO2017037670 (ONCOARENDI THERAPEUTICS SP Z O O [PL]) [A] 1-35 * page 8, paragraph second * * claims 1,59 *; | [A]WO2021009209 (ONCOARENDI THERAPEUTICS SA [PL]) [A] 1-35 * paragraphs [0013] , [ 0017] * * claims 1,32 * | by applicant | PL440558B | US5284656 | US5451569 | - BMC Evol Biol, (20070000), vol. Jun 26, pages 7 - 96 | - LEE et al., "Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury", Annu Rev Physiol, (20110000), vol. 73, doi:10.1146/annurev-physiol-012110-142250, pages 479 - 501, XP008140981 DOI: http://dx.doi.org/10.1146/annurev-physiol-012110-142250 | - JOHANSEN et al., "Identification of proteins secreted by human osteoblastic cells in culture", Journal of Bone & Mineral Research, (19920000), vol. 7, pages 501 - 512 | - REHLI et al., "Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation", Genomics, (19970000), vol. 43, no. 2, doi:10.1006/geno.1997.4778, pages 221 - 5, XP004459259 DOI: http://dx.doi.org/10.1006/geno.1997.4778 | - RENKEMA et al., "Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages", Eur J Biochem, (19980000), vol. 251, doi:10.1046/j.1432-1327.1998.2510504.x, pages 504 - 509, XP002107586 DOI: http://dx.doi.org/10.1046/j.1432-1327.1998.2510504.x | - CHUANET, "Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor a2", Cell Rep., (20130000), vol. 4, no. 4, pages 830 - 841 | - SHAO et al., "YKL-40, a secreted glycoprotein, promotes tumor angiogenesis", Oncogene, (20090000), vol. 28, no. 50, doi:10.1038/onc.2009.292, pages 4456 - 4468, XP055254598 DOI: http://dx.doi.org/10.1038/onc.2009.292 | - GENG et al., "Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer", J Exp Clin Cancer Res, (20180000), vol. 37, doi:10.1186/s13046-018-0876-2, page 208, XP055594440 DOI: http://dx.doi.org/10.1186/s13046-018-0876-2 | - LOW et al., "Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9", Oncotarget., (20150000), vol. 6, pages 36535 - 50 | - BOUVET et al., "Peripheral blood mononuclear cell response to YKL-40 and Galectin-3 in cystic fibrosis", Cytokine, (20210000), vol. 146, doi:10.1016/j.cyto.2021.155635, page 155635, XP086731277 DOI: http://dx.doi.org/10.1016/j.cyto.2021.155635 | - LEE et al., "Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling", Yonsei Med J, (20090000), vol. 50, pages 22 - 30 | - LEE et al., "Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury", Annu Rev Physiol, (20110000), vol. 73, doi:10.1146/annurev-physiol-012110-142250, pages 479 - 501, XP008140981 DOI: http://dx.doi.org/10.1146/annurev-physiol-012110-142250 | - LEE et al., "Role of breast regression protein-39/YKL-40 in asthma and allergic responses", Allergy Asthma Immunol Res, (20100000), vol. 2, pages 20 - 7 | - LEE et al., "Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis", J Exp Med, (20090000), vol. 206, pages 1149 - 66 | - DELA CRUZ et al., "Chitinase 3-like-1 (Chi311) Regulation of Streptococcus pneumoniae Lung Infection", Cell Host Microbe, (20120000), vol. 12, pages 34 - 4 | - JOHANSEN et al., "A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid", Br J Rheumatol, (19930000), vol. 32, doi:10.1093/rheumatology/32.11.949, pages 949 - 55, XP002041907 DOI: http://dx.doi.org/10.1093/rheumatology/32.11.949 | - MUSZYNSKI et al., "Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease", Curr Neuropharmacol, (20170000), vol. 15, no. 6, pages 906 - 917 | - JOHANSEN et al., "Is YKL-40 a new therapeutic target in cancer", Expert Opin Ther Targets., (20170000), vol. 11, no. 2, doi:10.1517/14728222.11.2.219, pages 219 - 34, XP008125745 DOI: http://dx.doi.org/10.1517/14728222.11.2.219 | - FAIBISH et al., "A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers", Mol Cancer Ther, (20110000), vol. 10, no. 5, doi:10.1158/1535-7163.MCT-10-0868, pages 742 - 51, XP055253693 DOI: http://dx.doi.org/10.1158/1535-7163.MCT-10-0868 | - PARK et al., "G721-0282 inhibits cell growth and induces apoptosis in human osteosarcoma through down-regulation of the STAT3 pathway", International journal of biological sciences, (20200000), vol. 16, no. 2, pages 330 - 341 | - LEE et al., "A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Ra2-mediated JNK-AP-1 signals", Mol Oncol, (20220000), vol. 16, no. 2, pages 508 - 526 | - FRANCESCONE et al., J Biol Chem, (20110000), vol. 286, pages 15332 - 43 | - KU et al., Int J Cancer, (20110000), vol. 128, pages 1316 - 26 | - ZHANG et al., Cancer, (20100000), vol. 116, page 2688 | - JOHANSEN et al., Breast Cancer Res Treat, (20030000), vol. 80, pages 15 - 21 | - FIJNEMAN et al., Clin Cancer Res, (20120000), vol. 18, page 2613 | - CHEN et al., Am J Pathol, (20110000), vol. 179, page 1494 | - WANG et al., Tumour Biol, (20150000), vol. 36, pages 901 - 7 | - JOHANSEN et al., Lung Cancer, (20040000), vol. 46, pages 333 - 40 | - CORRADI et al., Anticancer Res, (20131200), vol. 33, no. 12, page 5517 | - MA et al., Cancer Res, (20150000), vol. 75, pages 487 - 96 | - HOGDALL et al., BMC Cancer, (20090000), vol. 9, page 8 | - DUPONT et al., J Clin Oncol, (20040000), vol. 22, page 3330 | - NGERNYUANG et al., Int J Biochem Cell Biol, (20140000), vol. 51, pages 45 - 52 | - JEET et al., Endocr Relat Cancer, (20140000), vol. 21, page 723 | - PAN et al., J Cancer Res Clin Oncol, (20130000), vol. 139, pages 1043 - 54 | - LI et al., Chin Med J, (20120000), vol. 125, page 1777 | - ZHANGG et al., Tumour Biol, (20140000), vol. 35, pages 12131 - 7 | - MACTIER et al., J Proteome Res, (20110000), vol. 10, page 1030 | - MARCHESI, Vet Pathol, (20060000), vol. 43, pages 773 - 6 | - MARCHESI, J Vet Med A Physiol Pathol Clin Med, (20030000), vol. 50, page 103 | - QUERSHI, Genes Cancer, (20110000), vol. 2, page 74 | - EURICH, World J Gastroenterol, (20090000), vol. 15, page 5249 | - ROSLINDJOHANSEN, Methods of Mol Biol, (20090000), vol. 511, page 159 | - JOHANSEN, Cancer Epidemiol. Biomarkers Prev., (20060000), vol. 15, no. 2, pages 194 - 202 | - VALEYRE et al., "Sarcoidosis", Lancet, (20140000), vol. 383, no. 9923, pages 1155 - 67 | - LONG et al., "Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis", Eur Respir J, (20170000), vol. 23, pages 49 - 51 | - JOHANSEN et al., "Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity", Respir Med, (20050000), vol. 99, no. 4, doi:10.1016/j.rmed.2004.09.016, pages 396 - 402, XP004780205 DOI: http://dx.doi.org/10.1016/j.rmed.2004.09.016 | - RICHELDI et al., "Idiopathic pulmonary fibrosis", Lancet, (20170000), vol. 389, no. 10082, pages 1941 - 1952 | - FURUHASHI et al., "Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis", Respir Med, (20100000), vol. 104, no. 8, pages 1204 - 10, XP027106590 | - VIJ et al., "Peripheral blood biomarkers in idiopathic pulmonary fibrosis", Transl Res, (20120000), vol. 159, no. 4, doi:10.1016/j.trsl.2012.01.012, pages 218 - 27, XP055240430 DOI: http://dx.doi.org/10.1016/j.trsl.2012.01.012 | - KORTHAGEN et al., "Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis", Respir Med, (20110100), vol. 105, no. 1, pages 106 - 13, XP027541956 | - PAPI et al., Asthma. Lancet, (20180000), vol. 391, no. 10122, pages 783 - 800 | - RABE et al., "Chronic obstructive pulmonary disease", Lancet, (20170000), vol. 389, no. 10082, pages 1931 - 1940 | - XIANG et al., "The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review", Int J Chron Obstruct Pulmon Dis, (20180000), vol. 13, pages 409 - 418 | - XIANG et al., "The serum YKL-40 is a useful biomarker for asthma", European Respiratory Journal, (20170000), vol. 50, page PA3566 | - ISSELBACHER et al., Internal Medicine, Harrison's Principles, (19960000), pages 1814 - 1882 | - "Soluble Polymer-Enzyme Adducts", ABUCHOWSKIDAVIS, Enzymes as Drugs, Wiley-Interscience, (19810000), pages 367 - 383 | - NEWMARK et al., J Appl Biochem, (19820000), vol. 4, pages 185 - 9 | - ADJEI et al., Pharm Res, (19900000), vol. 7, pages 565 - 569 | - ADJEI et al., Int J Pharmaceutics, (19900000), vol. 63, pages 135 - 144 | - BRAQUET et al., J Cardiovasc Pharmacol, (19890000), vol. 13, pages 143 - 146 | - HUBBARD et al., Annal Int Med, (19890000), vol. 3, pages 206 - 212 | - SMITH et al., J Clin Invest, (19890000), vol. 84, pages 1145 - 1146 | - DEBS et al., J Immunol, (19880000), vol. 140, pages 3482 - 3488 | - LANGER R, Science, (19900000), vol. 249, pages 1527 - 33 | - SAWHNEY H S et al., Macromolecules, (19930000), vol. 26, pages 581 - 7 | - The Peptides;, Academic Press, (19810000), vol. 3 | - JOCHEN LEHMANN, Chemie der Kohlenhydrate: Monosaccharide und Derivate,, Georg Thieme Verlag, (19740000), vol. 15/1 | US19930181171 |